Kalydeco, developed by Vertex Pharmaceuticals Inc. in collaboration with the Cystic Fibrosis Foundation and approved by the FDA in January 2012, was awarded The Wall Street Journal’s 2012 Technology Innovation Award in the Medicine and Biotech category.
Winners for the award were selected for innovation that went beyond the conventional processes in their field, surpassed marginal improvements, and had a wide impact in the community. The Wall Street Journal went on to call Kalydeco “an example of personalized medicine.”
“Kalydeco opens exciting new doors to research and drug development that may ultimately help us treat all people with cystic fibrosis,” said Robert J. Beall, PhD, president and CEO of the Cystic Fibrosis Foundation. The foundation has raised and invested a substantial amount of funding to help develop many cystic fibrosis drugs and therapies available today, including $75 million for Vertex’s cystic fibrosis program.
Source: The Wall Street Journal